{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T12:15:18Z","timestamp":1783167318765,"version":"3.54.6"},"reference-count":61,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82371074"],"award-info":[{"award-number":["82371074"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012401","name":"Beijing Science and Technology Planning Project","doi-asserted-by":"publisher","award":["Z231100004823021"],"award-info":[{"award-number":["Z231100004823021"]}],"id":[{"id":"10.13039\/501100012401","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC3403300"],"award-info":[{"award-number":["2023YFC3403300"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Asia-Pacific Journal of Ophthalmology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.apjo.2026.100320","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T07:08:12Z","timestamp":1776755292000},"page":"100320","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["ZVS101e: AAV-mediated gene replacement therapy for Bietti crystalline corneoretinal dystrophy (BCD)"],"prefix":"10.1016","volume":"15","author":[{"given":"Liping","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4320-4041","authenticated-orcid":false,"given":"Wang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinlu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4814-4364","authenticated-orcid":false,"given":"Shaohong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9101-4461","authenticated-orcid":false,"given":"Baoyuan","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2063-783X","authenticated-orcid":false,"given":"Fan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuping","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiu Ying Enne","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis S.C.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apjo.2026.100320_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2025.101377","article-title":"Unravelling CYP4V2: Clinical features, genetic insights, pathogenic mechanisms and therapeutic strategies in Bietti crystalline corneoretinal dystrophy","volume":"107","author":"Jia","year":"2025","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.apjo.2026.100320_bib2","doi-asserted-by":"crossref","first-page":"953","DOI":"10.2147\/OPTH.S388292","article-title":"Diagnostic and management strategies of Bietti crystalline dystrophy: Current perspectives","volume":"17","author":"Saatci","year":"2023","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.apjo.2026.100320_bib3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1167\/iovs.65.4.25","article-title":"Longitudinal natural history study of visual function in Bietti crystalline dystrophy: implications for early intervention","volume":"65","author":"Han","year":"2024","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.apjo.2026.100320_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2021.101037","article-title":"Dynamic lipid turnover in photoreceptors and retinal pigment epithelium throughout life","volume":"89","author":"Lewandowski","year":"2022","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.apjo.2026.100320_bib5","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1016\/j.ymthe.2020.07.024","article-title":"PSCs reveal PUFA-provoked mitochondrial stress as a central node potentiating RPE degeneration in Bietti\u2019s crystalline dystrophy","volume":"28","author":"Zhang","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.apjo.2026.100320_bib6","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1124\/dmd.109.028530","article-title":"Expression and characterization of CYP4V2 as a fatty acid omega-hydroxylase","volume":"37","author":"Nakano","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.apjo.2026.100320_bib7","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.2147\/OPTH.S185744","article-title":"Current perspectives in bietti crystalline dystrophy","volume":"13","author":"Garcia-Garcia","year":"2019","journal-title":"Clin Ohthalmol"},{"key":"10.1016\/j.apjo.2026.100320_bib8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41572-021-00265-2","article-title":"Age-related macular degeneration","volume":"7","author":"Fleckenstein","year":"2021","journal-title":"Nat Rev Dis Prim"},{"key":"10.1016\/j.apjo.2026.100320_bib9","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1093\/hmg\/ddac181","article-title":"AAV-mediated gene replacement therapy restores viability of BCD patient iPSC derived RPE cells and vision of Cyp4v3 knockout mice","volume":"32","author":"Jia","year":"2023","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.apjo.2026.100320_bib10","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/s41434-020-0159-3","article-title":"Treating Bietti crystalline dystrophy in a high fat diet-exacerbated murine model using gene therapy","volume":"27","author":"Qu","year":"2020","journal-title":"Gene Ther"},{"key":"10.1016\/j.apjo.2026.100320_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2025.101460","article-title":"Preclinical studies of an AAV8-CYP4V2 gene therapy VGR-R01 for the treatment of Bietti crystalline dystrophy","volume":"33","author":"Luo","year":"2025","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.apjo.2026.100320_bib12","doi-asserted-by":"crossref","DOI":"10.1002\/jgm.3721","article-title":"Gene therapy clinical trials worldwide to 2023-an update","volume":"26","author":"Ginn","year":"2024","journal-title":"J Gene Med"},{"key":"10.1016\/j.apjo.2026.100320_bib13","doi-asserted-by":"crossref","first-page":"9525","DOI":"10.1038\/s41598-022-12210-8","article-title":"AAV2-mediated gene therapy for Bietti crystalline dystrophy provides functional CYP4V2 in multiple relevant cell models","volume":"12","author":"Wang","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.apjo.2026.100320_bib14","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.177231","article-title":"Evaluating precision medicine approaches for gene therapy in patient-specific cellular models of Bietti crystalline dystrophy","volume":"9","author":"Li","year":"2024","journal-title":"JCI Insight"},{"key":"10.1016\/j.apjo.2026.100320_bib15","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1038\/s41467-024-48092-9","article-title":"vivo genome editing via CRISPR\/Cas9-mediated homology-independent targeted integration for Bietti crystalline corneoretinal dystrophy treatment","volume":"15","author":"Meng","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.apjo.2026.100320_bib16","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ymthe.2020.12.007","article-title":"Current clinical applications of in vivo gene therapy with AAVs","volume":"29","author":"Mendell","year":"2021","journal-title":"Mol Ther"},{"key":"10.1016\/j.apjo.2026.100320_bib17","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41434-020-0168-2","article-title":"Retinal gene therapy: an eye-opener of the 21st century","volume":"28","author":"Askou","year":"2021","journal-title":"Gene Ther"},{"key":"10.1016\/j.apjo.2026.100320_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2021.100975","article-title":"Early and late stage gene therapy interventions for inherited retinal degenerations","volume":"86","author":"Botto","year":"2022","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.apjo.2026.100320_bib19","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.molmed.2018.06.006","article-title":"Seeing the light after 25 years of retinal gene therapy","volume":"24","author":"Trapani","year":"2018","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.apjo.2026.100320_bib20","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s11095-018-2564-5","article-title":"Adeno-associated viral gene therapy for inherited retinal disease","volume":"36","author":"Ong","year":"2019","journal-title":"Pharm Res"},{"key":"10.1016\/j.apjo.2026.100320_bib21","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.tips.2021.03.004","article-title":"Delivering AAV to the central nervous and sensory systems","volume":"42","author":"Peters","year":"2021","journal-title":"Trends Pharm Sci"},{"issue":"3","key":"10.1016\/j.apjo.2026.100320_bib22","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.molmed.2022.01.003","article-title":"AAV capsid design: A Goldilocks challenge","volume":"28","author":"Zolotukhin","year":"2022","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.apjo.2026.100320_bib23","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apjo.2026.100320_bib24","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.apjo.2026.100320_bib25","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ymthe.2019.12.010","article-title":"AAV vector immunogenicity in humans: A long journey to successful gene transfer","volume":"28","author":"Costa Verdera","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.apjo.2026.100320_bib26","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41434-023-00436-8","article-title":"AAV2 vector optimization for retinal ganglion cell-targeted delivery of therapeutic genes","volume":"31","author":"Chaqour","year":"2024","journal-title":"Gene Ther"},{"key":"10.1016\/j.apjo.2026.100320_bib27","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav4523","article-title":"Intein-mediated protein trans-splicing expands adeno-associated virus transfer capacity in the retina","volume":"11","author":"Tornabene","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.apjo.2026.100320_bib28","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.ymthe.2017.11.019","article-title":"Triple vectors expand AAV transfer capacity in the retina","volume":"26","author":"Maddalena","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.apjo.2026.100320_bib29","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.neuron.2019.02.017","article-title":"Therapeutic AAV gene transfer to the nervous system: A clinical reality","volume":"101","author":"Hudry","year":"2019","journal-title":"Neuron"},{"key":"10.1016\/j.apjo.2026.100320_bib30","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1016\/j.neuron.2022.05.003","article-title":"Engineered AAVs for non-invasive gene delivery to rodent and non-human primate nervous systems","volume":"110","author":"Chen","year":"2022","journal-title":"Neuron"},{"key":"10.1016\/j.apjo.2026.100320_bib31","doi-asserted-by":"crossref","first-page":"88ra54","DOI":"10.1126\/scitranslmed.3002103","article-title":"Dosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey","volume":"3","author":"Vandenberghe","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.apjo.2026.100320_bib32","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1089\/hum.2016.111","article-title":"Evaluation of dose and safety of AAV7m8 and AAV8BP2 in the non-human primate retina","volume":"28","author":"Ramachandran","year":"2017","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.apjo.2026.100320_bib33","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.trsl.2012.12.007","article-title":"Gene therapy for retinal disease","volume":"161","author":"McClements","year":"2013","journal-title":"Transl Res"},{"key":"10.1016\/j.apjo.2026.100320_bib34","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/mt.2013.232","article-title":"Successful gene therapy in the RPGRIP1-deficient dog: a large model of cone-rod dystrophy","volume":"22","author":"Lh\u00e9riteau","year":"2014","journal-title":"Mol Ther"},{"key":"10.1016\/j.apjo.2026.100320_bib35","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.7150\/thno.89380","article-title":"Understanding AAV vector immunogenicity: from particle to patient","volume":"14","author":"Dhungel","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.apjo.2026.100320_bib36","doi-asserted-by":"crossref","first-page":"5785","DOI":"10.1073\/pnas.1821000116","article-title":"AAV cis-regulatory sequences are correlated with ocular toxicity","volume":"116","author":"Xiong","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.apjo.2026.100320_bib37","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1056\/NEJMoa2307798","article-title":"Death after high-dose rAAV9 gene therapy in a patient with Duchenne's muscular dystrophy","volume":"389","author":"Lek","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apjo.2026.100320_bib38","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1016\/j.ymthe.2017.08.018","article-title":"AAV8 can induce innate and adaptive immune response in the primate eye","volume":"25","author":"Reichel","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.apjo.2026.100320_bib39","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd3438","article-title":"Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses","volume":"13","author":"Chan","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.apjo.2026.100320_bib40","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/s41591-020-0763-1","article-title":"Initial results from a first-in-human gene therapy trial on X-linked retinitis pigmentosa caused by mutations in RPGR","volume":"26","author":"Cehajic-Kapetanovic","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.apjo.2026.100320_bib41","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41392-024-01806-3","article-title":"Gene replacement therapy in Bietti crystalline corneoretinal dystrophy: an open-label, single-arm, exploratory trial","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.apjo.2026.100320_bib42","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.1016\/j.ymthe.2024.10.017","article-title":"Recombinant adeno-associated virus as a delivery platform for ocular gene therapy: A comprehensive review","volume":"32","author":"Wang","year":"2024","journal-title":"Mol Ther"},{"key":"10.1016\/j.apjo.2026.100320_bib43","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.3390\/v15102043","article-title":"Exploring the potential of cytomegalovirus-based vectors: A review","volume":"15","author":"Zeng","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.apjo.2026.100320_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2023.109758","article-title":"rAAV-compatible human mini promoters enhance transgene expression in rat retinal ganglion cells","volume":"239","author":"Araujo","year":"2024","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.apjo.2026.100320_bib45","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/2211-5463.13029","article-title":"The CAG promoter maintains high-level transgene expression in HEK293 cells","volume":"11","author":"Dou","year":"2021","journal-title":"FEBS Open Bio"},{"key":"10.1016\/j.apjo.2026.100320_bib46","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1186\/s13287-021-02651-9","article-title":"Multiocular organoids from human induced pluripotent stem cells displayed retinal, corneal, and retinal pigment epithelium lineages","volume":"12","author":"Isla-Magrane","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.apjo.2026.100320_bib47","doi-asserted-by":"crossref","DOI":"10.1242\/dev.189746","article-title":"Retinal organoids: a window into human retinal development","volume":"147","author":"O'Hara-Wright","year":"2020","journal-title":"Development"},{"key":"10.1016\/j.apjo.2026.100320_bib48","doi-asserted-by":"crossref","first-page":"6505","DOI":"10.1007\/s00018-021-03917-4","article-title":"A look into retinal organoids: methods, analytical techniques, and applications","volume":"78","author":"Afanasyeva","year":"2021","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.apjo.2026.100320_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.stemcr.2024.102393","article-title":"Transplantation of genome-edited retinal organoids restores some fundamental physiological functions coordinated with severely degenerated host retinas","volume":"20","author":"Watanabe","year":"2025","journal-title":"Stem Cell Rep"},{"key":"10.1016\/j.apjo.2026.100320_bib50","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1186\/s13287-021-02316-7","article-title":"Efficient differentiation of human embryonic stem cells to retinal pigment epithelium under defined conditions","volume":"12","author":"Limnios","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.apjo.2026.100320_bib51","doi-asserted-by":"crossref","first-page":"5572","DOI":"10.1167\/iovs.13-13717","article-title":"Generation and characterization of a murine model of Bietti Crystalline Dystrophy","volume":"55","author":"Lockhart","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.apjo.2026.100320_bib52","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/j.ymthe.2026.01.005","article-title":"Gene therapy for Bietti crystalline corneoretinal dystrophy: A phase 1\/2 clinical trial","volume":"34","author":"Yang","year":"2026","journal-title":"Mol Ther"},{"key":"10.1016\/j.apjo.2026.100320_bib53","first-page":"6389","article-title":"Phase 1\/2 gene therapy trial for Bietti crystalline corneoretinal dystrophy","volume":"66","author":"Yang","year":"2025","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.apjo.2026.100320_bib54","first-page":"81","article-title":"Subretinal gene therapy in patients with Bietti crystalline dystrophy: Preliminary results of a Phase 1\/2 clinical trial","volume":"32","author":"Yin","year":"2024","journal-title":"Mol Ther"},{"key":"10.1016\/j.apjo.2026.100320_bib55","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1001\/jamaophthalmol.2024.5619","article-title":"Safety and vision outcomes following gene therapy for Bietti crystalline dystrophy: A nonrandomized clinical trial","volume":"143","author":"Chen","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.apjo.2026.100320_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.apjo.2024.100098","article-title":"Practice patterns and challenges in managing inherited retinal diseases across Asia-Pacific: A survey from the APIED network","volume":"13","author":"Wong","year":"2024","journal-title":"Asia Pac J Ophthalmol"},{"key":"10.1016\/j.apjo.2026.100320_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.apjo.2023.100030","article-title":"Rationale and protocol paper for the Asia Pacific Network for inherited eye diseases","volume":"13","author":"Wong","year":"2024","journal-title":"Asia Pac J Ophthalmol"},{"key":"10.1016\/j.apjo.2026.100320_bib58","doi-asserted-by":"crossref","first-page":"847","DOI":"10.3390\/genes16070847","article-title":"Advances in precision therapeutics and gene therapy applications for retinal diseases: Impact and future directions","volume":"16","author":"AlEissa","year":"2025","journal-title":"Genes"},{"key":"10.1016\/j.apjo.2026.100320_bib59","article-title":"Artificial intelligence for retinal diseases","volume":"13","author":"Lim","year":"2024","journal-title":"Asia Pac J Ophthalmol (Philos"},{"key":"10.1016\/j.apjo.2026.100320_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.apjo.2024.100090","article-title":"Latest developments of generative artificial intelligence and applications in ophthalmology","volume":"13","author":"Feng","year":"2024","journal-title":"Asia Pac J Ophthalmol"},{"key":"10.1016\/j.apjo.2026.100320_bib61","article-title":"Advances and challenges in gene therapy for inherited retinal dystrophies: A comprehensive review","volume":"16","author":"Jain","year":"2024","journal-title":"Cureus"}],"container-title":["Asia-Pacific Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162098926000460?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162098926000460?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T11:17:11Z","timestamp":1783163831000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162098926000460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":61,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2162098926000460"],"URL":"https:\/\/doi.org\/10.1016\/j.apjo.2026.100320","relation":{},"ISSN":["2162-0989"],"issn-type":[{"value":"2162-0989","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ZVS101e: AAV-mediated gene replacement therapy for Bietti crystalline corneoretinal dystrophy (BCD)","name":"articletitle","label":"Article Title"},{"value":"Asia-Pacific Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apjo.2026.100320","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of Asia-Pacific Academy of Ophthalmology and Academy of Asia-Pacific Professors of Ophthalmology.","name":"copyright","label":"Copyright"}],"article-number":"100320"}}